510(k)

K131513: SCENAR (SCELAP, ENISAR, IPENS) CUTANEOUS ELECTRODE FAMILY

FDA 510(k) · Ritm Okb Zao · decided Jul 11, 2014

Key facts

510(k) number K131513
Device name SCENAR (SCELAP, ENISAR, IPENS) CUTANEOUS ELECTRODE FAMILY
Applicant Ritm Okb Zao
Product code GZJ
Subsequent product codes GXY
Date received May 28, 2013
Decision date Jul 11, 2014
Decision Substantially equivalent (SESE)
Submission type Traditional
Review panel Neurology
Medical specialty Neurology

At a glance

  • None MAUDE adverse event reports
  • None Recall events
  • None UDI device identifiers (GUDID)
  • 1–9 Predicate devices cited
  • None Later submissions citing this device
  • 100–999 510(k)s with this product code
  • Yes 510(k) summary on file
  • No 510(k) statement on file
  • Not listed On the FDA AI-enabled device list

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

Reading a 510(k)

Decision
SESE means the FDA found the device substantially equivalent to its predicate, so it may be marketed in the United States.
Predicates
Each clearance cites one or more legally marketed devices; the chain of predicates shows where a technology came from.
Product code
The three-letter code sets the device type, class and regulation, and groups competing clearances.
Summary or statement
Applicants file either a 510(k) summary of the safety and effectiveness information or a statement that it is available on request.

About 510(k) premarket notifications

A 510(k) is a premarket submission made to the FDA to demonstrate that a device is substantially equivalent to a legally marketed predicate device.

Source: U.S. Food and Drug Administration (FDA), 510(k) Premarket Notification database · Source date:

Browse all 510(k) premarket notifications